• Gilead Sciences and Merck recently reported that their Phase 3 ISLEND-1 and ISLEND-2 trials for a once-weekly oral HIV regimen met primary efficacy and safety goals, while Gilead also announced strong Phase 3 results for Livdelzi in primary biliary cholangitis and secured FDA approval for Hepcludex in hepatitis delta virus.
• Together, these developments highlight Gilead’s effort to broaden its portfolio beyond daily HIV therapies, adding long-acting regimens and liver disease treatments that could reshape its future product mix.
• We’ll now examine how the once-weekly HIV regimen data and broader liver portfolio progress may influence Gilead’s existing investment narrative.

The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Gilead Sciences Investment Narrative Recap

To own Gilead today, you need to believe its HIV franchise can evolve toward long‑acting regimens while newer areas like oncology and liver disease steadily add diversification. The ISLEND once‑weekly HIV data reinforce that transition path, while Livdelzi and Hepcludex progress support a broader liver focus. In the near term, the key catalyst remains execution on lenacapavir‑based HIV launches, and the biggest risk is continued pricing and policy pressure on the core HIV portfolio; this week’s news does not materially change that balance.

Among the recent updates, the ISLEND‑1 and ISLEND‑2 once‑weekly HIV results are most relevant here. They sit alongside lenacapavir’s twice‑yearly injectable program and Livdelzi’s Phase 3 PBC data as part of a larger effort to refresh Gilead’s HIV and liver franchises. Together, these programs could influence how quickly Gilead can offset any future HIV pricing pressure and eventual patent expiries by shifting patients into newer regimens and adding incremental liver disease revenue streams.

Yet, while the science looks encouraging, investors should also be aware that ongoing HIV pricing pressure and future patent expiries could still...

Gilead Sciences' narrative projects $34.5 billion revenue and $10.8 billion earnings by 2029.

Uncover how Gilead Sciences' forecasts yield a $157.83 fair value, a 25% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already penciling in about US$38.6 billion of revenue and US$12.3 billion of earnings by 2029, but the latest HIV and liver updates could either reinforce that optimism or underscore how reliant it is on launches like lenacapavir and Trodelvy actually delivering as hoped.

Explore 7 other fair value estimates on Gilead Sciences - why the stock might be worth over 2x more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Gilead Sciences research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Gilead Sciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Gilead Sciences' overall financial health at a glance.

Want Some Alternatives?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• Outshine the giants: these 14 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.